compound glp-1 fda How Crackdowns Are Affecting Use In 2025 FDA Phasing Out Compounded GLP-1

The situation is improving a little for Wegovy patients but 83% of patients with coverage still face barriers, including the Byzantine processes involved in securing prior authorizations and documenting compliance with step therapy requirements

What matters more is consistency in side effect management

doi: 10.1007/s12020-019-02055-z 93 PintoLCFalcettaMRRadosDVLeitaoCBGrossJL

Progesterone-related water retention and increased appetite often slow visible progress during the luteal phase

Meanwhile, Chinese companies are rapidly advancing through fast following, innovation and licensing, with key developments including Innovents mazdutide, Innogens supaglutide, Hengruis oral candidate HRS-7535, United Laboratories licensing of its first-in-class triple-G (GLP-1, gastric inhibitory polypeptide (GIP) and glucagon) a gonist to Novo Nordisk and Ascletis positive Phase 1 results for its oral + injection candidate, ASC30

Oh my god